This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Japan Tobacco Inc.

Drug Names(s): JTE151, JTE 151

Description: JTE-151 is an oral retinoid-related orphan receptor gamma antagonist which suppresses overactive immune response via inhibition of ROR gamma related to activation of Th17 cells (IL-17-producing T helper cells).

Deal Structure: JT and Orphagen
In January 2009, Orphagen Pharmaceuticals announced that it has entered into a Collaboration and License Agreement with Japan Tobacco to discover, develop and commercialize drugs in the areas of immunology and autoimmunity. Under the agreement, in effect since April 2008, JT has anexclusive license in Japan and options for exclusive licenses in the rest of the world. Financial terms were not disclosed.

Partners: Orphagen Pharmaceuticals

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug